1Lam JS, Leppert JT, Vemulapalli SN, et al. Secondary Hormonal Therapy for Advanced Prostate Cancer [ J ]. J Urol,2006,175 ( 1 ) :27 - 34.
2Bubley GJ, Carducci M, Dahut W, et al. Eligibility and Response Guidelines for Phase Ⅱ Clinical Trials in Androgen-Independent Prostate Cancer: Recommendations From the Prostate-Specific Antigen Working Group[J]. J Clin. Oncol,1999,17( 11 ):3 461 -3 467.
3Heidenreich A,Aus G, Bolla M, et al. EAU Guidelines on Prostate Cancer[ J ]. Eur Urol,2008 ,53 ( 1 ) :68 - 80.
4Fossa SD, Slee PH, Brausi M, et al. Flutamide versus prednisome in patients with prostate cancer symptom atically progressing after androgen-ablative therapy: a phase Ⅲ study of the European organization for research and treatment of cancer genitourinary group[ J]. J Clin Oncol,2001,19( 1 ) :62-71.
5Kucuk O, Fisher E, Moinpour CM, et al. Phase Ⅱ trial of bicalutamide in patients with advanced prostate cancer in whom conventional hormonal therapy failed: a Southwest Oncology Group study ( SWOG 9235 ) [ J ]. Urology,2001,58 ( 1 ) :53 - 58.
7Kassouf W,Tanguay S,Aprikian AG ,et al. Nilutamide as second line hormone therapy for prostate cancer after androgen ablation fails[J].J Urol,2RB,169(5) :1 745 - 1 746.
8Small EJ, Halabi S, Dawson NA, et al. Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a phase Ⅲ trial ( CALGB 9583 ) [J]. J Clin Oncol, 2004,22 (6) :1 025 -1 033.
9Koutsilieris M, Mitsiades C, Dimopoulos T, et al. A combination therapy of dexamethasone and somatostatin analog reintroduces objective clinical response to LHRH analog in androgen ablation-refractory prostate cancer patients[ J ]. J Clin Endocrinol Metab ,2001,86 ( 12 ) : 5 729 - 5 736.
10Sciarra A, Salciccia S. New treatment strategies in the management of hormone refractory prostate cancer (HRPC) : only chemotherapy [J]. Eur Urol, 2007,52 (4) :945 -947.
2Scher HI, Steineck G, Kelly WK. Hormone-refractory ( D3 ) prostate cancer:refining the concept. Urology,1995,46:142-148.
3Bubley GJ, Carducci M, Dahut W, et al. Eligibility and response guidelines for phase Ⅱ clinical trial in androgen-independent prostate cancer:recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol, 1999,17:3461-3467.
4Lara JP, Meyers FJ. Treatment options in androgen-independent prostate cancer. Cancer Invest, 1999,17:137-144.
5Joyce R,Fenton MA,Rode P,et al. High dose bicalutamide for androgen independent prostate cancer: effect of prior hormonal therapy.J Urol, 1998,159:149-153.
6Kucuk O, Fisher E, Moinpour CM, et al. Phase Ⅱ trial of bicalutamide in patients with advanced prostate cancer in whom conventional hormonal therapy failed: a Southwest Oncology Group Study ( SWOG 9235). Urology,2001,58 :53-58.
7Kolvenbag JCM, Blackledge GRP. Worldwide activity and safety of bicalutamide: A summary review. Urology, 1996,47: 70 -79.
